Omeros Corporation (OMER) Bucks Biotech Sell-Off

Omeros Corporation (NASDAQ:OMER) will begin a late-stage study of its atypical hemolytic uremic syndrome treatment

Mar 8, 2016 at 12:22 PM
facebook X logo linkedin

Despite a broader sell-off of biotechnology stocks -- per a 2.2% decline in the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) -- drugmaker Omeros Corporation (NASDAQ:OMER) is soaring on news the company will kick off a Phase 3 study for OMS721 -- its drug used to treat atypical hemolytic uremic syndrome. Additionally, OMER reported a slimmer-than-expected fourth-quarter loss. Against this backdrop, the stock is up 18.6% at $15.40 -- on track for its biggest one-day percentage gain in six months -- and call volume has jumped to seven times the average intraday rate.

While OMER option volume is relatively light on an absolute basis -- just over 1,300 total contracts have traded so far today -- calls are outpacing puts by a 17-to-1 margin. This is just more of the same, as evidenced by the stock's top-heavy 20-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 7.21.

Outside of the options arena, however, sentiment among traders is skewed toward the skeptical side. Specifically, short interest accounts for nearly 27% of OMER's available float, or 39.3 times the average daily trading volume. As such, it's possible some of today's bull gap is a result of shorts covering. Plus, a portion of the recent call buying -- particularly at out-of-the-money strikes -- could be a result of shorts hedging their bearish bets.

On the charts, Omeros Corporation (NASDAQ:OMER) has been a long-term laggard, losing 49% since hitting a record high of $30.23 in mid-August. What's more, today's rally is stalling out near the $16 mark -- a level that served as resistance in late 2015.


Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical  levels, and top economic stories straight to your inbox.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI